AstraZeneca AB et al v. Alkem Laboratories Limited et al
| AstraZeneca AB, AstraZeneca UK Limited and AstraZeneca Pharmaceuticals LP |
| Alkem Laboratories Limited and S&B Pharma, Inc. |
| 1:2022cv00354 |
| March 18, 2022 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on May 11, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 13 STIPULATION TO EXTEND TIME to ANSWER Complaint to June 13, 2022 - filed by Alkem Laboratories Limited. (Stamoulis, Stamatios) |
SO ORDERED, re #13 STIPULATION and Proposed Order to Extend Time (*Reset Answer Deadlines: Alkem Laboratories Limited answer due 6/13/2022; S&B Pharma, Inc. answer due 6/13/2022). Signed by Judge Richard G. Andrews on 5/11/2022. (nms)
|
| Filing 12 NOTICE requesting Clerk to remove Angela C. Whitesell as co-counsel.. (Silver, Daniel) |
|
SO ORDERED, re #11 STIPULATION and Proposed Order to Extend Time (*Reset Answer Deadlines: Alkem Laboratories Limited answer due 5/11/2022; S&B Pharma, Inc. answer due 5/11/2022). Signed by Judge Richard G. Andrews on 4/11/2022. (nms)
|
| Filing 11 STIPULATION and Proposed Order to Extend Time - filed by Alkem Laboratories Limited, S&B Pharma, Inc.. (Stamoulis, Stamatios) Modified on 4/11/2022 (nms). |
| Filing 10 SUMMONS Returned Executed by AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. S&B Pharma, Inc. served on 3/21/2022, answer due 4/11/2022. (Joyce, Alexandra) |
| Filing 9 DECLARATION of Service of Alkem Laboratories Ltd., by AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Attachments: #1 Exhibits A-B)(Joyce, Alexandra) Modified on 3/25/2022 (nms). |
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) |
| Filing 8 Summonses Issued (please complete the top portion of the form and print out for use/service). (srs) |
| Filing 7 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca Pharmaceuticals LP filed by AstraZeneca Pharmaceuticals LP. (srs) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca AB filed by AstraZeneca AB. (srs) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca UK Limited filed by AstraZeneca UK Limited. (srs) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE46,276 ;10,300,065. (srs) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No Earlier than February 1, 2022. Date of Expiration of Patent: RE46,276 - 10/30/2024; 10,300,065 - 1/27/2036. Thirty Month Stay Deadline: No earlier than August 1, 2024. (srs) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (srs) |
| Filing 1 COMPLAINT FOR PATENT INFRINGEMENT filed against Alkem Laboratories Limited, S&B Pharma, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3828706.) - filed by AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Attachments: #1 Exhibit A-C, #2 Civil Cover Sheet)(srs) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
